Zdrowie i gospodarka · 18/06/2018

FDA Seeks Public Comment on Proposed Meetings with Biosimilar Biological Product Sponsors and Applicants

The Food and Drug Administration (FDA) is requesting public input on its proposed formal meetings with biosimilar biological product sponsors and applicants, as required by the Paperwork Reduction Act of 1995.